Success Metrics

Clinical Success Rate
77.8%

Based on 14 completed trials

Completion Rate
78%(14/18)
Active Trials
6(16%)
Results Posted
36%(5 trials)
Terminated
4(11%)

Phase Distribution

Ph phase_4
10
27%
Ph early_phase_1
1
3%
Ph phase_1
3
8%
Ph phase_3
6
16%
Ph not_applicable
11
30%
Ph phase_2
4
11%

Phase Distribution

4

Early Stage

4

Mid Stage

16

Late Stage

Phase Distribution35 total trials
Early Phase 1First-in-human
1(2.9%)
Phase 1Safety & dosage
3(8.6%)
Phase 2Efficacy & side effects
4(11.4%)
Phase 3Large-scale testing
6(17.1%)
Phase 4Post-market surveillance
10(28.6%)
N/ANon-phased studies
11(31.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

73.7%

14 of 19 finished

Non-Completion Rate

26.3%

5 ended early

Currently Active

6

trials recruiting

Total Trials

37

all time

Status Distribution
Active(9)
Completed(14)
Terminated(5)
Other(9)

Detailed Status

Completed14
unknown9
Recruiting4
Terminated4
Not yet recruiting3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
37
Active
6
Success Rate
77.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (2.9%)
Phase 13 (8.6%)
Phase 24 (11.4%)
Phase 36 (17.1%)
Phase 410 (28.6%)
N/A11 (31.4%)

Trials by Status

recruiting411%
completed1438%
active_not_recruiting25%
withdrawn13%
not_yet_recruiting38%
terminated411%
unknown924%

Recent Activity

Clinical Trials (37)

Showing 20 of 37 trialsScroll for more
NCT06212102Phase 2

Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation

Recruiting
NCT07212712Not Applicable

The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans

Not Yet Recruiting
NCT05326087Phase 3

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A

Not Yet Recruiting
NCT06613100Phase 1

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

Recruiting
NCT06390904Phase 2

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients

Active Not Recruiting
NCT06379113Phase 2

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Recruiting
NCT04414748Phase 3

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A

Completed
NCT05057546Phase 4

Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)

Active Not Recruiting
NCT05447208Phase 3

Effect of GH on the Blastocyst Euploid Rate in AMA Patients

Recruiting
NCT00702234

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)

Completed
NCT06396390Phase 4

Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes

Not Yet Recruiting
NCT00696878Phase 3

Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)

Completed
NCT04327934Early Phase 1

Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome

Terminated
NCT04043520Phase 4

Bioenergetic Effects of Aging and Menopause (BEAM)

Unknown
NCT04414761Phase 3

Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response

Completed
NCT04108039Not Applicable

Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.

Completed
NCT04071574Phase 1

Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility

Completed
NCT05759871Phase 1

Ovarian Stimulation With FSH Alone Versus FSH Plus GnRH Antagonist in an Oocyte Donor/Recipient Programme

Unknown
NCT05574894Phase 3

Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort Study

Completed
NCT03876912Not Applicable

The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
37